Literature DB >> 30723788

National and State Estimates of COPD Morbidity and Mortality - United States, 2014-2015.

Jamie Sullivan1,2, Vira Pravosud3, David M Mannino3,4, Keith Siegel1, Radmila Choate3, Tracie Sullivan1.   

Abstract

Background: Chronic obstructive pulmonary disease (COPD) remains a leading cause of disability and death in the United States. The "COPD in the United States" project gathered data about the impact of COPD to highlight variability across states and provide a single point of access to data for state decision makers, the public health community and advocates. This report provides a summary of COPD-related morbidity and mortality in the United States and individual states during 2014-2015 (some metrics contain data from other years).
Methods: We used data from multiple sources ( the Behavioral Risk Factor Surveillance System [BRFSS], the Centers for Disease Control and Prevention (CDC) Wide-ranging ONline Data for Epidemiologic Research online database, the CDC's chronic disease indicators data, Centers from Medicare and Medicaid Services Chronic Conditions Data Warehouse, Medical Expenditures Panel Survey and the American Association of Cardiovascular and Pulmonary Rehabilitation Pulmonary Rehabilitation Directory) to estimate 10 national and state-specific COPD metrics (prevalence, hospitalizations and emergency department visits, 30-day hospital readmissions, mortality, vaccinations, smoking prevalence, per capita medical cost, and the number of COPD patients per a pulmonary rehabilitation program) and to calculate average score across the 10 metrics. Additionally, we used BRFSS data to calculate the prevalence of common comorbid diseases among people who also report having a diagnosis of COPD.
Results: During 2014-2015, 5.9% of adults (more than 15.9 million) reported having been told by their health care professional that they had COPD. The age-adjusted prevalence ranged from 3.7% for Puerto Rico and Hawaii, to 12% for West Virginia. The average score, 1 being best and 5 being worst, of the overall COPD burden based on the 10 key metrics ranged from 1.5 for Puerto Rico and Utah to 4.6 for West Virginia.
Conclusion: The level of COPD morbidity and mortality is severe throughout the United States. There is considerable variability in COPD metrics by state. These differences may be useful in identifying and addressing policy gaps in the public health approach to COPD and in implementing the COPD National Action Plan.

Entities:  

Keywords:  Behavioral Risk Factor Surveillance System; chronic obstructive pulmonary disease; comorbidities; copd; morbidity; mortality; prevalence; state data

Year:  2018        PMID: 30723788      PMCID: PMC6361472          DOI: 10.15326/jcopdf.5.4.2018.0157

Source DB:  PubMed          Journal:  Chronic Obstr Pulm Dis        ISSN: 2372-952X


  3 in total

1.  Total and state-specific medical and absenteeism costs of COPD among adults aged ≥ 18 years in the United States for 2010 and projections through 2020.

Authors:  Earl S Ford; Louise B Murphy; Olga Khavjou; Wayne H Giles; James B Holt; Janet B Croft
Journal:  Chest       Date:  2015-01       Impact factor: 9.410

2.  COPD surveillance--United States, 1999-2011.

Authors:  Earl S Ford; Janet B Croft; David M Mannino; Anne G Wheaton; Xingyou Zhang; Wayne H Giles
Journal:  Chest       Date:  2013-07       Impact factor: 9.410

3.  Urban-Rural County and State Differences in Chronic Obstructive Pulmonary Disease - United States, 2015.

Authors:  Janet B Croft; Anne G Wheaton; Yong Liu; Fang Xu; Hua Lu; Kevin A Matthews; Timothy J Cunningham; Yan Wang; James B Holt
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2018-02-23       Impact factor: 17.586

  3 in total
  25 in total

1.  Lung proteomic biomarkers associated with chronic obstructive pulmonary disease.

Authors:  Yu-Hang Zhang; Michael R Hoopmann; Peter J Castaldi; Kirsten A Simonsen; Mukul K Midha; Michael H Cho; Gerard J Criner; Raphael Bueno; Jiangyuan Liu; Robert L Moritz; Edwin K Silverman
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2021-10-20       Impact factor: 5.464

2.  Self-reported COPD Medication Use and Adherence in the COPD Foundation Patient- Powered Registry Network.

Authors:  Cara B Pasquale; Radmila Choate; Gretchen McCreary; Richard A Mularski; William Clark; MaryEllen Houlihan; Elisha Malanga; Barbara P Yawn
Journal:  Chronic Obstr Pulm Dis       Date:  2021-10-28

3.  Pilot Study of a Patient Experience with an ELLIPTA Inhaler Electronic Medication Monitor and Associated Integrated System: A Prospective Observational Study Using the COPD Patient-Powered Research Network.

Authors:  Barbara P Yawn; Gretchen M McCreary; John A Linnell; Cara B Pasquale; Elisha Malanga; Radmila Choate; David A Stempel; Rahul Gondalia; Leanne Kaye; Kathryn A Collison; Benjamin S Wu; Daniel Gratie; Richard H Stanford; Ryan Tomlinson
Journal:  Chronic Obstr Pulm Dis       Date:  2021-10-28

4.  The Impact of Twice-Daily Indacaterol/Glycopyrrolate on the Components of Health-Related Quality of Life and Dyspnea in Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease.

Authors:  Donald A Mahler; Edward Kerwin; Lindsey Murray; Carole Dembek
Journal:  Chronic Obstr Pulm Dis       Date:  2019-10-23

5.  Mucus Plugs and Emphysema in the Pathophysiology of Airflow Obstruction and Hypoxemia in Smokers.

Authors:  Eleanor M Dunican; Brett M Elicker; Travis Henry; David S Gierada; Mark L Schiebler; Wayne Anderson; Igor Barjaktarevic; R Graham Barr; Eugene R Bleecker; Richard C Boucher; Russell Bowler; Stephanie A Christenson; Alejandro Comellas; Christopher B Cooper; David Couper; Gerard J Criner; Mark Dransfield; Claire M Doerschuk; M Bradley Drummond; Nadia N Hansel; MeiLan K Han; Annette T Hastie; Eric A Hoffman; Jerry A Krishnan; Stephen C Lazarus; Fernando J Martinez; Charles E McCulloch; Wanda K O'Neal; Victor E Ortega; Robert Paine; Stephen Peters; Joyce D Schroeder; Prescott G Woodruff; John V Fahy
Journal:  Am J Respir Crit Care Med       Date:  2021-04-15       Impact factor: 21.405

6.  Prioritization and Refinement of Patient-Informed Value Elements as Attributes for Chronic Obstructive Pulmonary Disease Treatment Preferences.

Authors:  Julia F Slejko; Yoon Duk Hong; Jamie L Sullivan; Robert M Reed; Susan dosReis
Journal:  Patient       Date:  2021-02-08       Impact factor: 3.883

7.  Associations of tobacco retailer availability with chronic obstructive pulmonary disease related hospital outcomes, United States, 2014.

Authors:  Amanda Y Kong; Christopher D Baggett; Nisha C Gottfredson; Kurt M Ribisl; Paul L Delamater; Shelley D Golden
Journal:  Health Place       Date:  2020-12-01       Impact factor: 4.078

8.  Vaccine Effectiveness Against Influenza-Associated Lower Respiratory Tract Infections in Hospitalized Adults, Louisville, Kentucky, 2010-2013.

Authors:  Eric J Chow; Melissa A Rolfes; Ruth L Carrico; Stephen Furmanek; Julio A Ramirez; Jill M Ferdinands; Alicia M Fry; Manish M Patel
Journal:  Open Forum Infect Dis       Date:  2020-06-30       Impact factor: 3.835

9.  Beyond tobacco - the secondary impact of substance misuse in chronic obstructive lung disease.

Authors:  M Macmurdo; R Lopez; B L Udeh; J Zein
Journal:  J Asthma       Date:  2020-11-19       Impact factor: 2.515

10.  The complexity of mental health care for people with COPD: a qualitative study of clinicians' perspectives.

Authors:  Juliet Wang; Karen Willis; Elizabeth Barson; Natasha Smallwood
Journal:  NPJ Prim Care Respir Med       Date:  2021-07-22       Impact factor: 2.871

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.